MS FOR NEUROLOGY TRAINEES SPEAKERS

DR PATRICK AOUAD (chair) received a Bachelor of Medical Science, majoring in neuroscience with a particular interest in neuroimaging whilst serving as the President of the Medical Science Society at the University of Sydney. He completed his medical degree followed an MPhil examining early CT signs in acute ischaemic stroke. He went onto advanced training in neurology with a special interest in neuroimmunology. Dr Aouad received the registrar of the year award and undertook a further fellowship in neuroimmunology/MS obtaining his FRACP in 2016. He is a staff specialist at Liverpool Hospital, works privately on the north shore and continues to pursue research in the field through independent investigation and clinical trials. He has a strong interest in education and founded the MS for Neurology Trainees day. He holds a position as honorary fellow and research supervisor at the University of Sydney.

PROFESSOR SIMON BROADLEY is Dean and Head of the School of Medicine at Griffith University. He is also a Senior Staff Specialist in Neurology at the Gold Coast Hospital. Professor Broadley undertook undergraduate studies at the University of Manchester, before completing his basic physician training in Liverpool and advanced training in neurology in Bristol. As part of his advanced training in neurology, he completed his studies with a Doctor of Philosophy in a thesis entitled "The Genetics of a Complex Trait: Multiple Sclerosis". He continues to contribute to the neurological service at Gold Coast Hospital through the MS Clinic and general neurology service. His research interests include the epidemiology and genetics of MS, neuromyelitis optica and SUNCT syndrome, as well as clinical trials of novel therapeutic agents for multiple sclerosis.

PROFESSOR JEANETTE LECHNER-SCOTT was born in Germany and completed her medical degree and her PhD on pain pathways at the University of Heidelberg and began her residency at the University Hospital of Freiburg. Most of her neurology training was completed at the University Hospital of Basel, Switzerland, where she joined the internationally highly successful MS research group of Professor Ludwig Kappos. After moving to Australia, Professor Lechner-Scott started a specialised MS clinic in Newcastle, which has steadily grown to be to one of the largest in the country with over 700 patients. With national and international collaborations (ANZGene and IMSGC) her group has identified over 190 gene regions that predispose to MS. They were also the first to identify gene regulation methods (hypomethylation in HLA-DRB 1501) which might well explain the interaction between genes and known environmental risk factors like smoking, sun exposure and glandular fever. Her team currently applies new MRI technologies to assess what molecules influence clinical disability including cognition and fatigue.

DR BENJAMIN TREWIN is a consultant neurologist currently completing a PhD focusing on a comparative analysis of the clinical and radiological features of MOGAD, MS, and NMOSD. He is the recipient of the University Postgraduate Award Scholarship and the Antibody-associated Demyelination Scholarship at the University of Sydney. Dr Trewin completed his BAppSc (Exercise & Sport Science & Nutrition) in 2007 and MBBS (USyd) in 2012. He completed his specialty training at St. Vincent's Hospital, Campbelltown Hospital, Royal Prince Alfred Hospital, and Concord Repatriation General Hospital. Dr Trewin is a published first author in two peer-reviewed journals,

he has authored numerous conference abstracts and delivered an oral platform presentation at the International Society of Neuroimmunology meeting in 2018. He is passionate about medical education and advancing our knowledge of demyelinating disorders.

ASSOCIATE PROFESSOR ANNEKE VAN DER WALT is an academic Neurologist with subspecialty training in multiple sclerosis and neuroimmunology as well as neuro-ophthalmology. She leads the MS and Neuro-ophthalmology Research Group at the Central Clinical School, Monash University, Australia. She completed her undergraduate training in South Africa before relocating to Australia where she completed specialist training in Neurology and a PhD in Neuroscience under supervision of Professors Trevor Kilpatrick and Helmut Butzkueven at the University of Melbourne. Her research interests include cerebellar dysfunction in MS, and MS cognition, and women's health. She leads several large national and international studies on digital biomarkers in MS. Associate Professor van der Walt is the Chief Operating Officer of the MSBae foundation. Her clinical roles include appointments as the Director, MSNI Unit and Neuro-ophthalmology Service at Alfred Health, Melbourne.

PROFESSOR TOMAS KALINCIK is a Dame Kate Campbell Professorial Fellow, the head of the Clinical Outcomes Research (CORe) Unit at the University of Melbourne and of the MS Centre at the Royal Melbourne Hospital. Together with his research group, CORe, Tomas specialises in analytics of observational data in neurology. He is the chair of the Scientific Leadership Group of the global MSBase collaboration. He has led several international collaborative research initiatives, including studies of comparative effectiveness of MS therapies, management of treatment failure and individual treatment response. His main research interests span treatment outcomes in MS and other neuroimmunological diseases, individualised therapy, prognostics (including emerging biomarkers), causal inference, epidemiology and utility of volumetric MRI. He is the convenor of the international CORe Advanced Statistics Course, endorsed by the European Committee for Treatment and Research in MS.

PROFESSOR BRUCE TAYLOR of the Neurological Research University of Tasmania was appointed as a principal research fellow at the Menzies Institute for Medical Research in Hobart as a 50/50 conjoint position with the Royal Hobart Hospital in 2007. Since taking up this position, he has established the ongoing Tasmanian Genes and Prevalence study, become an executive member of the Australian & NZ MS genes consortium (ANZGENE) funded by MS research Australia and an ARC linkage grant, established the NHMRC funded AUSLONG and AUSLONG2 studies, become an executive member of the Australian & NZ NMO study, become a steering committee member of the international MS genetic consortium, and established and obtained funding for the Prevention of MS with Vitamin D Australia & NZ (PREVANZ) study funded by MS research Australia ($3.5 million). Professor Taylor is a medical graduate of the University of Tasmania and completed specialist training in Neurology in WA and at the Mayo Clinic USA, returning to Australia in 1996 to begin clinical practice.

ASSOCIATE PROFESSOR TODD HARDY is a staff specialist neurologist at Concord Hospital, clinical Associate Professor in medicine at the University of Sydney and Co-Director of the MS Clinic at the Brain and Mind Centre. He is Co-Chair of the NSW MS Clinical Trials Network and a Principal Investigator on a number of MS clinical trials. He is also Co-Editor of *Advances in Clinical Neuroscience and Rehabilitation*. His clinical and research interests are in the field of neuroimmunology. His main focus is on multiple sclerosis, including atypical forms of demyelination, and other neuroinflammatory diseases of the central nervous system (CNS), especially Susac's syndrome. In 2018 he travelled to the Mayo clinic to study atypical demyelinating disease as a recipient of the MS Research Australia Ian Ballard Travel Award.

ASSOCIATE PROFESSOR STEPHEN REDDEL is a staff specialist neurologist at Concord Repatriation & General Hospital Sydney, and consultant neurologist at the Brain & Mind Centre, University of Sydney. He trained in neurology at Royal Prince Alfred Hospital, Sydney, and at the Radcliffe Infirmary, Oxford, and has a PhD in the immunology of the Anti-Phospholipid Syndrome. He heads the neuroimmunology clinic at Concord Hospital, which specialises in the safe treatment of neurological conditions requiring immunotherapy, including multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and a host of rarer diseases. He has a longstanding interest in clinical safety. This focus on safety has also included the Alemtuzumab in MS Safety Study (AMS3), which lead to the development of Bloodwatch and Medical Safety Systems, a multinational medical IT safety company. He has research interests in myasthenia gravis, examining the function of anti-MuSK antibodies and the homeostasis of the neuromuscular junction; in neuroimmunology and MS, and in neurogenetics including the muscular dystrophies and inherited neuropathies.



DR HEIDI BEADNALL (MBBS FRACP PhD) is a Staff Specialist Neurologist at the Royal Prince Alfred Hospital and Clinical Lecturer at the Brain and Mind Centre, the University of Sydney. She is also an investigator in the MS Clinical Trials Unit based at the Brain and Mind Centre. Her main areas of interest are multiple sclerosis and neuroimmunology. She was awarded a PhD in the use of quantitative magnetic resonance imaging brain atrophy measurement techniques in real-world multiple sclerosis patients, with regard to clinical correlations and use in MS clinical practice.

DR MIKE BOGGILD has over 20 years' experience in neurology, initially as a consultant neurologist at The Walton Centre in Liverpool, UK before becoming Director of Neurology at The Townsville Hospital in 2012. He has a special interest in Multiple Sclerosis (MS) and was the visiting neurologist to The Isle of Man for 15 years with experience across the range of neurological disorders. After completing his neurology training in Leicester, Stoke-on-Trent and Newcastle-upon-Tyne he undertook a sabbatical at MS centres in the United States before setting up the MS service in Liverpool in 1996. The Walton multi-disciplinary MS service was later recognised by the MS society as the best comprehensive service in UK. He initiated a number of investigator led clinical studies in addition to participating in numerous multi-centre trials. In 2002 he was appointed as clinical lead and subsequently chief investigator for the 5,000 patient UK MS risk-sharing scheme; a prospective 10-year study of the long-term outcomes and cost-effectiveness of disease modifying therapies, a role he relinquished in 2012 on moving to Australia.

PROFESSOR HELMUT BUTZKUEVEN (MBBS 1992, PhD 2002) is an academic neurologist specialising in management of Multiple Sclerosis (MS) and real-world MS outcomes research. He is the van Cleef Roet professor of Neuroscience Research at the Central Clinical School, Monash University and Direcotr of Neurolgy at Alfred Health, Melbourne. He is also the Managing Director of the MSBase Foundation (www.msbase.org), a global online MS cohort study which commenced in 2004, with more than 74,000 patients enrolled from 130 centres to date. His overarching research theme and clinical interest is the use of registry data, clinical MRI data, cognitive testing, genomics and patient self-monitoring devices and applications to evaluate treatment strategies and trial methodology to optimize benefit, safety and discovery of MS therapies.

DR JENNIFER MASSEY is a Neurologist with an interest in neuroimmunology and MS. She completed her undergraduate training at UWA graduating with honours and worked in Western Australia prior to beginning Neurology Advanced Training in NSW. She completed neurology training in 2017 and then undertook a PhD through UNSW in Immune reconstitution treatments for MS and clonal kinetics of AHSCT, for which she is the recipient of an MSRA postgraduate scholarship and a post-doctorate fellowship. She remains passionate about the about the personalised care of patients with MS.

DR JOHN PARRATT is a neurologist at Royal North Shore Hospital overseeing a large Multiple Sclerosis clinic and an academic at the University of Sydney. His interests include identifying pathogenic mechanisms and causal pathways of neuroimmunological diseases that include multiple sclerosis, autoimmune encephalitis and vasculitis. His research focuses upon identifying novel serum and CSF antibodies that localise specific targets in these diseases. His vision is to use a multi-modal approach to identify groups of patients with specific disease mechanisms and CNS targets that can be fully elucidated to develop individualised therapies. He completed his PhD on the epidemiology of MS in Scotland and received the inaugural Neil and Norma Hill Fellowship to study MS at the University of Sydney. He was trained in neuropathology by Professor John Prineas, who has contributed seminally to the histopathological analysis of MS. He has published widely and is building a network of epidemiological, laboratory and clinical collaborations that will facilitate the comprehensive study of neuroimmunological diseases prospectively.